Novartis Terminates Agreement With BioArctic
Novartis has terminated its option, collaboration and license agreement with BioArctic.
Related stories
Neurocrine Biosciences Reports Q3 Revenue of $1.12B
Q3 revenue was $1.12 billion, compared with a FactSet estimate of $1.04 billion.
M impact | EQUITY | Nov 02, 2026, 09:59 PM UTC
Pershing Square Q3 Revenue Falls
M impact | EQUITY | Nov 02, 2026, 09:57 PM UTC
Three Anavex Directors Resign Over Strategic Differences
Anavex Life Sciences says three directors resigned over strategic differences.
M impact | EQUITY | Nov 02, 2026, 09:48 PM UTC
IIP Q3 Net Income Rises; Revenue Also Increases Year Over Year
IIP reported higher net income and revenue in the third quarter of 2026 compared with a year earlier.
M impact | EQUITY | Nov 02, 2026, 09:48 PM UTC
EverQuote Q3 2026 revenue grows 25% on carrier demand
Management attributed Q3 2026 revenue growth of 25% to strong carrier demand.
M impact | EQUITY | Nov 02, 2026, 09:48 PM UTC
Gibson Energy Says Higher Marketing Activity Drove Q3 Earnings Growth
M impact | EQUITY | Nov 02, 2026, 09:47 PM UTC